Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
Sujan Piya, Hong Mu, Seemana Bhattacharya, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 5, pp. 1878-1894
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem, Craig M. Crews
Cell (2020) Vol. 181, Iss. 1, pp. 102-114
Open Access | Times Cited: 768
A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization
Tingting Yang, Yuzhu Hu, Junming Miao, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 6, pp. 2658-2671
Open Access | Times Cited: 70
Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine
Sara S. Bashraheel, Alexander Dömlingꝉ, Sayed K. Goda
Biomedicine & Pharmacotherapy (2020) Vol. 125, pp. 110009-110009
Open Access | Times Cited: 97
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Yonghan He, Sajid Khan, Zhiguang Huo, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 91
Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
Ewelina Kulikowski, Brooke D. Rakai, Norman C.W. Wong
Medicinal Research Reviews (2020) Vol. 41, Iss. 1, pp. 223-245
Open Access | Times Cited: 89
Targeting CXCR4 in AML and ALL
Daniel Cancilla, Michael P. Rettig, John F. DiPersio
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 87
Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia
Noortje van Gils, Fedor Denkers, Linda Smit
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 78
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia
Bryann Pardieu, Justine Pasanisi, Frank Ling, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1585-1595
Open Access | Times Cited: 45
Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach
Qiuxia Chen, Chuan Liu, Wei Wang, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 1, pp. 25-33
Open Access | Times Cited: 29
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
Degraders upgraded: the rise of PROTACs in hematological malignancies
Joshua Casan, John F. Seymour
Blood (2024) Vol. 143, Iss. 13, pp. 1218-1230
Closed Access | Times Cited: 15
Wnt signaling: Modulating tumor-associated macrophages and related immunotherapeutic insights
Yimeng Yuan, Dapeng Wu, Yifan Hou, et al.
Biochemical Pharmacology (2024) Vol. 223, pp. 116154-116154
Open Access | Times Cited: 13
Landscape of driver mutations and their clinical effects on Down syndrome–related myeloid neoplasms
Tomohiko Sato, Kenichi Yoshida, Tsutomu Toki, et al.
Blood (2024) Vol. 143, Iss. 25, pp. 2627-2643
Closed Access | Times Cited: 8
Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
Ning Sun, Chaowei Ren, Ying Kong, et al.
European Journal of Medicinal Chemistry (2020) Vol. 193, pp. 112190-112190
Closed Access | Times Cited: 64
Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities
Tony Marchand, Sandra Pinho
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 55
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
Shuiyan Wu, You Jiang, Yi Hong, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 49
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
Yunchao Chang, Jaeki Min, Jamie Jarusiewicz, et al.
Blood (2021) Vol. 138, Iss. 23, pp. 2313-2326
Open Access | Times Cited: 47
Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior
Vigneshwari Easwar Kumar, R Nambiar, Cristabelle De Souza, et al.
Cells (2022) Vol. 11, Iss. 9, pp. 1403-1403
Open Access | Times Cited: 33
BRD4: New hope in the battle against glioblastoma
Weichen Duan, Miao Yu, Jiajia Chen
Pharmacological Research (2023) Vol. 191, pp. 106767-106767
Open Access | Times Cited: 18
BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL
Karin Bauer, Alexander W. Hauswirth, Karoline V. Gleixner, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 9, pp. 1721-1731
Open Access | Times Cited: 6
Divergent Processing of Cell Stress Signals as the Basis of Cancer Progression: Licensing NFκB on Chromatin
Spiros Vlahopoulos
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8621-8621
Open Access | Times Cited: 6
EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma
Guangtong Deng, Furong Zeng, Yi He, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 2
Open Access | Times Cited: 24
Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL
Sujan Piya, Ya‐Ling Yang, Seemana Bhattacharya, et al.
Leukemia (2022) Vol. 36, Iss. 5, pp. 1261-1273
Open Access | Times Cited: 24
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling
Alexander Marr, Madeline Halpin, Dominique Corbin, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy
Qi Liu, Bayonle Aminu, Olivia Roscow, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 791-791
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top